CD36 expression in monocytes and ankylosing spondylitis

doi:10.3969/j.issn.2095-4344.2015.29.020

Abstract

Abstract:

BACKGROUND: Ankylosing spondylitis is an autoimmune disease involved in chronic systemic inflammation. Tumor necrosis factor and interleukin-6 levels increased in patients with ankylosing spondylitis. Inflammatory factors such as tumor necrosis factor and interleukin-6 can suppress CD36 expression in monocytes.
OBJECTIVE: To analyze the correlation between CD36 expression in monocytes and ankylosing spondylitis.
METHODS: A total of 84 newly diagnosed ankylosing spondylitis patients and 111 healthy individuals were included in this study. CD36 expressions in monocytes in ankylosing spondylitis patients and healthy individuals were tested using flow cytometer; meanwhile, biochemistry, immunology, routine blood examination and related inflammatory markers were determined between the two groups.
RESULTS AND CONCLUSION: Results of baseline data in both groups demonstrated that CD36 fluorescence intensity in monocytes was significantly lower in patients with ankylosing spondylitis compared with healthy controls (P < 0.01). CD36 fluorescence intensity in monocytes was negatively correlated with C-reactive protein, erythrocyte sedimentation, interleukin-6 and tumor necrosis factor. In addition, CD36 fluorescence intensity in monocytes was negatively correlated with BASDAI score. Logistic regression analysis showed that erythrocyte sedimentation, interleukin-6, tumor necrosis factor and CD36 fluorescence intensity in monocytes were associated with ankylosing spondylitis, and risk factors for ankylosing spondylitis (P < 0.05). These findings confirm that inflammatory cytokine in patients with ankylosing spondylitis weakened the expression of CD36 in monocytes. There was a remarkable association between low expression of CD36 expression in monocytes and ankylosing spondylitis. CD36 expression of monocytes clinically may be considered to be an effective indicator to evaluate inflammation and disease activity in patients with ankylosing spondylitis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Antigens, CD36, Spondylitis, Ankylosing, Tumor Necrosis Factors, Interleukin-6

CLC Number:

R318

Qin Wei, Lian Kai, Guo Qing . CD36 expression in monocytes and ankylosing spondylitis [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(29): 4695-4699.

Figures/Tables 4

References

[1] El Maghraoui A.Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications.Eur J Intern Med. 2011;22(6):554-560 560.

[2] Braun J, van den Berg R, Baraliakos X, et al.2010 update of the ASAS/EULAR recommendations for the management ofankylosing spondylitis. Annals of the Rheumatic Diseases. 2011;70(6):896-904

[3] Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al.The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease.Medicine.2009；88(6)358-365.

[4] Ge Y, Elghetany MT.CD36: a multiligand molecule. Lab Hematol.2005;11(1):31- 37.

[5] Collot-Teixeira S, Martin J, McDermott-Roe C,et al. CD36 and macrophages in atherosclerosis. Cardiovasc Res.2007;75: 468-477.

[6] Boyer JF, Balard P, Authier H, et al.Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther.2007; 9(2):R22.

[7] Wang C, Liao Q, Hu Y,et al.T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med. 2015;9(1):250-256.

[8] 冯家烜,徐茂锦.CD36与糖尿病动脉粥样硬化关系的研究进展[J], 实用糖尿病杂志,2013,5(1):3-6.

[9] Ramos-Arellano LE, Muñoz-Valle JF, De la Cruz-Mosso U, et al.Circulating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects. BMC Cardiovasc Disord. 2014;14:54.

[10] Kim EH, Tolhurst AT, Szeto HH, Cho SH.Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke.CNS Neurosci Ther.2015;21(4):385-391.

[11] 杨敏,李林瑞,孟燕妮,等.凝血酶敏感蛋白-1及其受体CD36在支气管肺发育不良患儿中的表达及临床意义[J].中外医学研究, 2015,11(13):1-5.

[12] 罗俊一,马依彤,谢翔,等.CD36基因多态性与急性冠脉综合征关联性的研究. 中华流行病学杂志2014, 2(35):200-204.

[13] Peng YF, Cao L, Zeng YH, et al. Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with rheumatoid arthritis. Open Med. 2015; 10: 249-253.

[14] Peng YF, Zhang Q, Cao L, et al. Red blood cell distribution width: a potential marker estimating disease activity of ankylosing spondylitis. Int J Clin Exp Med. 2014;7(12):5289-5295.

[15] Kawakami M,Murase T,Ogawa H,et al.Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-l1 cells. J Biochem. 1987;101:331-338.

[16] 申成凯,吕成昱,王英振,等.白细胞介素10启动子基因多态性与强直性脊柱炎的易感性[J].中国组织工程研究,2013,20(17): 3793-3799.

[17] 彭隽,贾汝汉,党建中,等.CD36在高糖诱导的大鼠肾小球系膜细胞凋亡中的作用及机制[J].中华肾脏病杂志,2014,30(5):370-376.

[18] Huang JT, Welch JS, Ricote M, et al.Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase.Nature.1999; 400:378-382.

[19] Draude G, Lorenz RL.TGF-beta1 downregulates CD36 and scavenger receptor A but upregulates LOX-1 in human macrophages.Am J Physiol Heart Circ Physiol. 2000;278: 1042-1048.

[20] Rubic T, Lorenz RL.Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as antiatherosclerotic mechanisms of interleukin-10. Cardiovasc Res.2006;69:527-535.

[21] Suzawa M, Takada I, Yanagisawa J,et al.Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade.Nat Cell Biol 2003;5:224-230.

[22] Sung CK, She H, Xiong S,et al.Tumor necrosis factoralpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2004;286:722-729.

[23] Boyer JF, Balard P, Authier H,et al.“Tumor necrosis factor alpha and adalimumab diffrentially regulate CD36 expression in human monocytes,” ArthritisResearchandThrapy.2007; 99(2):22-25.

[24] Peng YF, Zhang ZX, Cao W, et al.The association between red blood cell distribution width and acute pancreatitis associated lung injury in patients with acute pancreatitis. Open Med.2015; 10: 176-179.

[25] Driscoll WS, Vaisar T, Tang J, et al.Raines.Macrophage ADAM17 defiiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflmmatory phenotype,” Circulation Research.2013;113(1):52-61.

[26] Asada K,Sasaki S,Suda T,et al.Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med.2004; 169:195-200.

[27] Chung EY, Liu J, Homma Y, et al.Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity.2007;27:952–964.

[28] Bottcher A,Gaipl US,Furnrohr BG,et al.Involvement of phosphatidylserine,alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primarynecrotic lymphocytes by macrophages.Arthritis Rheum.2006;54: 927-938.

[29] Hu YF, Yeh HI, Tsao HM, et al..Impact of circulating monocyte CD36 level on atrial fibrillation and subsequent catheter ablation.Heart Rhythm.2011; 8(5):650-656.

[30] Serghides L,Kain KC.Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/ macrophages. Immunol.2001;166:6742-6748.

[31] Boyer JF, Balard P, Authier H, et al. Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther. 2007;9: 22.

[32] Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.Cell.1998;93:241-252.